Literature DB >> 15660242

Effects of combined lamotrigine and valproate on basal and stimulated extracellular amino acids and monoamines in the hippocampus of freely moving rats.

Shagufta Ahmad1, Leslie J Fowler, Peter S Whitton.   

Abstract

The antiepileptic drugs sodium valproate (VPA) and lamotrigine (LTG) are increasingly used in combination in patients in whom monotherapy has failed to control seizures. Although these drugs are known to interact pharmacokinetically, several authors have proposed a pharmacodynamic interaction between the two. In order to investigate this we have studied the effects of combined treatment with LTG and VPA on basal and stimulated extracellular aspartate (ASP), glutamate (GLU), taurine (TAU), gamma amino butyric acid (GABA), 5-hydroxytryptamine (5-HT) and dopamine (DA) release in the hippocampus of freely moving rats using microdialysis. Additionally, we measured the possible effect of VPA on LTG in plasma, whole brain and dialysates. Neither LTG (10 mg/kg) nor VPA (300 mg/kg) given alone significantly altered basal levels of ASP, GLU or TAU. When given together, however, the two drugs significantly reduced extracellular ASP and GLU while increasing TAU levels. In the case of GABA, LTG was without effect on basal levels of the transmitter, but these increased following VPA and this persisted with both drugs. When transmitter release was stimulated by 50 muM veratridine, marked increases in the release of all amino acids occurred and this was decreased by LTG in all cases. VPA alone only altered GABA release, increasing it by approximately the same extent as basal GABA. For all of the amino acids studied, however, VPA reversed the decreases in release seen after LTG. VPA and LTG increased and decreased respectively basal 5-HT and DA. When given together the increase in extracellular 5-HT was greatly prolonged, but no effect on DA release was seen. When 5-HT release was evoked by veratridine this was increased by VPA and no other treatment. With DA, however, neither drug alone altered evoked release, but the two combined led to a marked increase. Co-administration of VPA with LTG showed no significant effect of this combination on LTG in any of the three compartments studied indicating that in this case a significant pharmacokinetic contribution to our findings is unlikely, which suggests that there is a probable pharmacodynamic interaction of the two drugs.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15660242     DOI: 10.1007/s00210-004-1008-4

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  44 in total

1.  Effects of valproate and other antiepileptic drugs on brain glutamate, glutamine, and GABA in patients with refractory complex partial seizures.

Authors:  O A Petroff; D L Rothman; K L Behar; F Hyder; R H Mattson
Journal:  Seizure       Date:  1999-04       Impact factor: 3.184

2.  Lamotrigine inhibition of glutamate release from isolated cerebrocortical nerve terminals (synaptosomes) by suppression of voltage-activated calcium channel activity.

Authors:  S J Wang; T S Sihra; P W Gean
Journal:  Neuroreport       Date:  2001-07-20       Impact factor: 1.837

3.  Lamotrigine and carbamazepine affect differently the release of D-[3H]aspartate from mouse cerebral cortex slices: involvement of NO.

Authors:  I Afanas'ev; V Kudrin; K S Rayevsky; V Varga; P Saransaari; S S Oja
Journal:  Neurochem Res       Date:  1999-09       Impact factor: 3.996

4.  Biphasic effects of carbamazepine on the dopaminergic system in rat striatum and hippocampus.

Authors:  M Okada; T Hirano; K Mizuno; T Chiba; Y Kawata; K Kiryu; K Wada; H Tasaki; S Kaneko
Journal:  Epilepsy Res       Date:  1997-09       Impact factor: 3.045

5.  Valproate and carbamazepine increase prefrontal dopamine release by 5-HT1A receptor activation.

Authors:  J Ichikawa; H Y Meltzer
Journal:  Eur J Pharmacol       Date:  1999-09-03       Impact factor: 4.432

6.  Effect of isonicotinic acid hydrazide on extracellular amino acids and convulsions in the rat: reversal of neurochemical and behavioural deficits by sodium valproate.

Authors:  C S Biggs; B R Pearce; L J Fowler; P S Whitton
Journal:  J Neurochem       Date:  1994-12       Impact factor: 5.372

7.  Studies on the mechanism of action of the novel anticonvulsant lamotrigine (Lamictal) using primary neurological cultures from rat cortex.

Authors:  G Lees; M J Leach
Journal:  Brain Res       Date:  1993-05-28       Impact factor: 3.252

Review 8.  Current limitations of antiepileptic drug therapy: a conference review.

Authors:  C L P Deckers; P Genton; G J Sills; D Schmidt
Journal:  Epilepsy Res       Date:  2003-02       Impact factor: 3.045

9.  Regional effects of sodium valproate on extracellular concentrations of 5-hydroxytryptamine, dopamine, and their metabolites in the rat brain: an in vivo microdialysis study.

Authors:  C S Biggs; B R Pearce; L J Fowler; P S Whitton
Journal:  J Neurochem       Date:  1992-11       Impact factor: 5.372

10.  Lamotrigine potentiates the antiseizure activity of some anticonvulsants in DBA/2 mice.

Authors:  G De Sarro; F Nava; U Aguglia; A De Sarro
Journal:  Neuropharmacology       Date:  1996-02       Impact factor: 5.250

View more
  16 in total

1.  Chronic valproate treatment blocks D2-like receptor-mediated brain signaling via arachidonic acid in rats.

Authors:  Epolia Ramadan; Mireille Basselin; Ameer Y Taha; Yewon Cheon; Lisa Chang; Mei Chen; Stanley I Rapoport
Journal:  Neuropharmacology       Date:  2011-08-03       Impact factor: 5.250

Review 2.  Taurine interaction with neurotransmitter receptors in the CNS: an update.

Authors:  Jan Albrecht; Arne Schousboe
Journal:  Neurochem Res       Date:  2005-12       Impact factor: 3.996

3.  Effect of lamotrigine and carbamazepine on corticotropin-releasing factor-associated serotonergic transmission in rat dorsal raphe nucleus.

Authors:  Shunske Tanahashi; Satoshi Yamamura; Masanori Nakagawa; Eishi Motomura; Motohiro Okada
Journal:  Psychopharmacology (Berl)       Date:  2011-09-27       Impact factor: 4.530

4.  Protective Effect of Nerolidol Against Pentylenetetrazol-Induced Kindling, Oxidative Stress and Associated Behavioral Comorbidities in Mice.

Authors:  Dilpreet Kaur; Priyanka Pahwa; Rajesh Kumar Goel
Journal:  Neurochem Res       Date:  2016-07-14       Impact factor: 3.996

Review 5.  Mood-stabilizers target the brain arachidonic acid cascade.

Authors:  Jagadeesh S Rao; Stanley I Rapoport
Journal:  Curr Mol Pharmacol       Date:  2009-06       Impact factor: 3.339

Review 6.  Proof of concept trials in bipolar disorder and major depressive disorder: a translational perspective in the search for improved treatments.

Authors:  Rodrigo Machado-Vieira; Carlos A Zarate
Journal:  Depress Anxiety       Date:  2011-02-24       Impact factor: 6.505

7.  Interaction of Delta sleep-inducing peptide and valproate on metaphit audiogenic seizure model in rats.

Authors:  Olivera Stanojlović; Dragan Hrncić; Aleksandra Rasić; Helena Loncar-Stevanović; Dragan Djuric; Veselinka Susić
Journal:  Cell Mol Neurobiol       Date:  2007-10-24       Impact factor: 5.046

8.  Bcl-2 rs956572 polymorphism is associated with increased anterior cingulate cortical glutamate in euthymic bipolar I disorder.

Authors:  Márcio Gerhardt Soeiro-de-Souza; Giacomo Salvadore; Ricardo Alberto Moreno; Maria Concepción Garcia Otaduy; Kalil T Chaim; Wagner F Gattaz; Carlos A Zarate; Rodrigo Machado-Vieira
Journal:  Neuropsychopharmacology       Date:  2012-10-17       Impact factor: 7.853

9.  Intracerebroventricular administration of ouabain alters synaptic plasticity and dopamine release in rat medial prefrontal cortex.

Authors:  Li Sui; Xiao-Jin Song; Jie Ren; Li-Hua Ju; Yan Wang
Journal:  J Neural Transm (Vienna)       Date:  2013-01-12       Impact factor: 3.575

Review 10.  Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders.

Authors:  Gerard Sanacora; Carlos A Zarate; John H Krystal; Husseini K Manji
Journal:  Nat Rev Drug Discov       Date:  2008-05       Impact factor: 84.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.